INS and liver disorder: Sulphonylureas/glinides are very effective on glucose levels, but, independently of liver disease, their use has been moved to third-line treatment in recent guidelines because novel drugs are safer, similarly effective, and not associated with the CV risk of insulin secretagogues.55 Their use should be even more discouraged in the presence of liver disease.